TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non–small-cell lung cancer
RS Herbst, D Prager, R Hermann… - Journal of clinical …, 2005 - ascopubs.org
Purpose Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor with single-agent activity in patients with non–small-cell lung cancer …
tyrosine kinase inhibitor with single-agent activity in patients with non–small-cell lung cancer …
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
Ipilimumab improves clinical outcomes when combined with nivolumab in metastatic non-
small cell lung cancer (NSCLC), but its efficacy and impact on the immune …
small cell lung cancer (NSCLC), but its efficacy and impact on the immune …
The BATTLE trial: personalizing therapy for lung cancer
Abstract The Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer
Elimination (BATTLE) trial represents the first completed prospective, biopsy-mandated …
Elimination (BATTLE) trial represents the first completed prospective, biopsy-mandated …
[HTML][HTML] Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated …
Purpose We investigated the efficacy of fluorouracil (FU), leucovorin, irinotecan, and
bevacizumab (FOLFIRI+ B) in a phase II trial in patients previously untreated for metastatic …
bevacizumab (FOLFIRI+ B) in a phase II trial in patients previously untreated for metastatic …
Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses
Abstract Purpose: The T790M gatekeeper mutation in the EGFR is acquired by some EGFR-
mutant non–small cell lung cancers (NSCLC) as they become resistant to selective tyrosine …
mutant non–small cell lung cancers (NSCLC) as they become resistant to selective tyrosine …
Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470
R Satchi-Fainaro, M Puder, JW Davies, HT Tran… - Nature medicine, 2004 - nature.com
Angiogenesis is crucial for tumor growth. Angiogenesis inhibitors, such as O-(chloracetyl-
carbamoyl) fumagillol (TNP-470), are thus emerging as a new class of anticancer drugs. In …
carbamoyl) fumagillol (TNP-470), are thus emerging as a new class of anticancer drugs. In …
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase …
HT Tran, Y Liu, AJ Zurita, Y Lin… - The lancet …, 2012 - thelancet.com
Background Several targeted drugs are approved for treatment of patients with metastatic
renal-cell cancer, but no validated biomarkers are available for prediction of clinical …
renal-cell cancer, but no validated biomarkers are available for prediction of clinical …
Phase I study of recombinant human endostatin in patients with advanced solid tumors
PURPOSE: Endostatin, a 20-kd fragment of collagen XVIII, is a potent inhibitor of
angiogenesis. We evaluated recombinant human endostatin (rh-Endo) in a phase I trial …
angiogenesis. We evaluated recombinant human endostatin (rh-Endo) in a phase I trial …
Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for iv BuCy2 in chronic …
BS Andersson, PF Thall, T Madden… - Biology of Blood and …, 2002 - astctjournal.org
Complete bioavailability of iv busulfan (Bu) provides dose assurance by reducing the
interdose and interpatient variability in Bu systemic exposure (Bu-SE) associated with the …
interdose and interpatient variability in Bu systemic exposure (Bu-SE) associated with the …
[HTML][HTML] Programmed death-ligand 1 heterogeneity and its impact on benefit from immune checkpoint inhibitors in NSCLC
Introduction Programmed death-ligand 1 (PD-L1) expression may vary in different disease
sites and at different time points of the disease course. We aimed to investigate PD-L1 …
sites and at different time points of the disease course. We aimed to investigate PD-L1 …